At what stage is this treatment used?
- Regorafenib (Stivarga®), a targeted therapy that comes in pill form, is a tyrosine kinase inhibitor (TKI). This kind of treatment is designed to target cancer cells and the blood vessels feeding them by interfering with chemical signals or pathways inside abnormal cells. Regorafenib targets the signaling of multiple growth factors involved in tumor angiogenesis, including VEGF receptors, Fibroblast Growth Factor (FGF) receptors, Platelet-Derived Growth Factor (PDGF) receptors, and the angiopoietin receptor TIE-2. Additional targets of regorafenib include RAF, BRAF, RET and KIT. Regorafenib is approved for treating patients with advanced (metastatic) colorectal cancer in the third-line setting, after the cancer has progressed or has recurred after multiple treatments.
Is this drug available via the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Regorafenib is not currently listed on the PBS as a subsidised treatment.
Download the Consumer Medicine Information (CMI) for Stivarga